The global market for Esophageal Cancer Drugs is estimated at US$12.7 Billion in 2023 and is projected to reach US$19.4 Billion by 2030, growing at a CAGR of 6.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Esophageal Squamous-Cell Carcinoma Drugs segment, which is expected to reach US$14.8 Billion by 2030 with a CAGR of a 6.4%. The Esophageal Adenocarcinoma Drugs segment is also set to grow at 5.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.5 Billion in 2023, and China, forecasted to grow at an impressive 10.0% CAGR to reach $4.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Esophageal Cancer Drugs Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Esophageal Cancer Drugs Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Esophageal Cancer Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CStone Pharmaceuticals, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 35 Featured):
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- CStone Pharmaceuticals
- Daiichi Sankyo Co., Ltd.
- HUTCHMED
- Innovent Biologics, Inc.
- Jacobio Pharmaceuticals
- Merck & Co., Inc.
- Oncolys BioPharma
- OncoTherapy Science
- Rakuten Medical
- Shanghai Henlius Biotech
- Shanghai Junshi Biosciences
- Shionogi, Inc.
- Taiho Pharmaceutical Co., Ltd.;
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Esophageal Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
3. MARKET TRENDS & DRIVERS
- Rising Global Incidence of Esophageal Cancer and Its Impact on Drug Development
- Breakthroughs in Immunotherapy for Esophageal Cancer
- Increasing Role of Genetics in Personalized Cancer Treatments
- Growth of Targeted Therapy Approaches
- Influence of Dietary and Lifestyle Factors on Esophageal Cancer Risk
- Emerging Markets Driving Growth in Cancer Care Infrastructure
- Regulatory Environment Influencing Drug Approval Processes
- Advances in Chemotherapy and Radiation Therapy Techniques
- Collaboration between Biotech and Pharmaceutical Giants
- Insurance Coverage and Reimbursement Issues Affecting Patient Access
- Technological Advances in Drug Delivery Systems
- Clinical Trial Innovations and Their Impact on Treatment Effectiveness
- Government Policies on Cancer Care and Prevention
- Safety Concerns and Side Effects of Current Treatment Options
- Global Health Initiatives and Collaborations for Cancer Control
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Esophageal Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 3: World Historic Review for Esophageal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 4: World 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Esophageal Squamous-Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Esophageal Squamous-Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 7: World 16-Year Perspective for Esophageal Squamous-Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Esophageal Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Esophageal Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 10: World 16-Year Perspective for Esophageal Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 16: World 16-Year Perspective for Targeted Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 19: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
UNITED STATES
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 21: USA Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 22: USA 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 23: USA Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 24: USA Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 25: USA 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 27: Canada Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 28: Canada 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 29: Canada Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 30: Canada Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 31: Canada 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
JAPAN
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 32: Japan Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 33: Japan Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 34: Japan 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 35: Japan Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 36: Japan Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 37: Japan 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
CHINA
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 38: China Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 39: China Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 40: China 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 41: China Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 42: China Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 43: China 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
EUROPE
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 44: Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 45: Europe Historic Review for Esophageal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 46: Europe 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 47: Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 48: Europe Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 49: Europe 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 51: Europe Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 52: Europe 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
FRANCE
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 53: France Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 54: France Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 55: France 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 56: France Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 57: France Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 58: France 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
GERMANY
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 59: Germany Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 60: Germany Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 61: Germany 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 62: Germany Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 63: Germany Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 64: Germany 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
ITALY
- Table 65: Italy Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 66: Italy Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 67: Italy 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 68: Italy Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 69: Italy Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 70: Italy 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 71: UK Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 72: UK Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 73: UK 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 74: UK Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 75: UK Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 76: UK 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
SPAIN
- Table 77: Spain Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 78: Spain Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 79: Spain 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 80: Spain Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 81: Spain Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 82: Spain 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
RUSSIA
- Table 83: Russia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 84: Russia Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 85: Russia 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 86: Russia Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 87: Russia Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 88: Russia 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 89: Rest of Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 90: Rest of Europe Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 91: Rest of Europe 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 96: Asia-Pacific Historic Review for Esophageal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 97: Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Esophageal Cancer Drugs by Cancer Type - Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Esophageal Squamous-Cell Carcinoma and Esophageal Adenocarcinoma for the Years 2014, 2024 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Esophageal Cancer Drugs by Therapy - Chemotherapy, Targeted Drug Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Esophageal Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Drug Therapy and Immunotherapy for the Years 2014, 2024 & 2030
AUSTRALIA
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
LATIN AMERICA
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
MIDDLE EAST
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
AFRICA
- Esophageal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- CStone Pharmaceuticals
- Daiichi Sankyo Co., Ltd.
- HUTCHMED
- Innovent Biologics, Inc.
- Jacobio Pharmaceuticals
- Merck & Co., Inc.
- Oncolys BioPharma
- OncoTherapy Science
- Rakuten Medical
- Shanghai Henlius Biotech
- Shanghai Junshi Biosciences
- Shionogi, Inc.
- Taiho Pharmaceutical Co., Ltd.;
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 269 |
Published | December 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 12.7 Billion |
Forecasted Market Value ( USD | $ 19.4 Billion |
Compound Annual Growth Rate | 6.2% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |